The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
|Videos|December 29, 2017
Experts Reflect on Oncology Advancements in 2017
Author(s)Onclive Team
Key opinion leaders share the biggest advancements in oncology made this past year.
Advertisement
Key opinion leaders share some of the biggest advancements in oncology in 2017.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5